Simmitinib hydrochloride

盐酸希美替尼

Report date: 2024/09/13 20:00:38
NME

Base Information

Drug NameSimmitinib hydrochloride
Drug Alias NameSOMCL-15-290
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsColony stimulating factor 1 receptor inhibitorsFibroblast growth factor receptors antagonists
TargetsFibroblast growth factor receptorsColony stimulating factor 1 receptorVascular endothelial growth factor receptor 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShanghai Runshi Pharmaceutical Technology Co Ltd
Inactive CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co Ltd
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A